23:09 , May 8, 2019 |  BC Extra  |  Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
02:06 , May 11, 2018 |  BC Innovations  |  Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
20:24 , Feb 23, 2018 |  BC Week In Review  |  Financial News

miRagen raises $38.5M in follow-on

MicroRNA company miRagen Therapeutics Inc. (NASDAQ:MGEN) raised $38.5 million on Feb. 8 through the sale of 7 million shares at $5.50 in a follow-on underwritten by Jefferies, Evercore, Deutsche Bank, Wedbush and Oppenheimer. The price...
00:35 , Oct 21, 2017 |  BioCentury  |  Product Development

Naked ambition

Proof-of-concept data from miRagen Therapeutics Inc. show systemic delivery of its lead candidate can shrink lesions in cutaneous T cell lymphoma, and that its oligonucleotide platform can achieve broad distribution and a long half-life without...
15:15 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

miRagen reports Phase I data of systemic microRNA therapy in CTCL

miRagen Therapeutics Inc. (NASDAQ:MGEN) reported interim data from 23 evaluable patients with mycosis fungoides-type cutaneous T cell lymphoma (CTCL) in the second part of an open-label, U.S Phase I trial showing that once-weekly 300, 600...
21:25 , Oct 13, 2017 |  BC Extra  |  Clinical News

miRagen reports systemic microRNA therapy data in CTCL

miRagen Therapeutics Inc. (NASDAQ:MGEN) reported interim data from the second part of an ongoing Phase I trial of MRG-106 in patients with mycosis fungoides-type cutaneous T cell lymphoma (CTCL). Among 23 patients receiving the systemically...
23:25 , Jun 9, 2017 |  BioCentury  |  Finance

ASCO ascent

Investors were keenly focused on immunotherapy combinations containing PD-1/L1 and IDO inhibitors going into this year’s American Society of Clinical Oncology meeting, but the biggest gainers were companies that generated positive clinical data for other...
19:48 , Feb 17, 2017 |  BC Week In Review  |  Financial News

Miragen completes venture financing

MicroRNA company Miragen Therapeutics Inc. (Boulder, Colo.) raised $40.7 million in a private placement immediately prior to the close of its merger with publicly listed Signal Genetics Inc. on Feb. 13 to form Miragen Therapeutics...
23:21 , Nov 3, 2016 |  BC Week In Review  |  Company News

Signal, miRagen deal

miRagen will merge with Signal to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain miRagen's name and trade on NASDAQ. The...
23:20 , Nov 1, 2016 |  BC Extra  |  Company News

miRagen finds public path via Signal merger

miRagen Therapeutics Inc. (Boulder, Colo.) will merge with Signal Genetics Inc. (NASDAQ:SGNL) to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain...